Digestive Health Newsletter

Finding Support When You Have Inflammatory Bowel Disease

Laura Strohmeyer, RN, CGRN

Volume 14, 
May 01, 2009

by Laura Strohmeyer, RN, CGRN

Laura Strohmeyer, RN, CGRN Laura Strohmeyer, RN, CGRN, has facilitated support groups for patients with Crohn's disease and ulcerative colitis in the Dallas area for the past eight years. She has lectured regionally and nationally about inflammatory bowel disease (IBD) and the role of support groups for IBD patients. She has practiced as a gastroenterology nurse manager for over 25 years, and has been certified in gastroenterology nursing for the past 19 years. Laura is a former member of the Board of Trustees of the North Texas chapter of the Crohn's and Colitis Foundation of America. Since 2006, she has served on the Board of Directors for the Society of Gastroenterology Nurses and Associates. Ms. Strohmeyer is currently the Clinical Director for AmSurg and works with outpatient gastroenterology centers in Texas and Oklahoma.

Table of Contents

Introduction

People with Crohn's disease or ulcerative colitis are continuously seeking education and support to help them manage their disease. They often find that dealing with the psychological impact of living with a chronic disease proves to be the greatest challenge. It is not surprising that chronic disease and its consequences can lead to stress, anxiety, and depression, or can worsen pre–existing emotional problems. Although we know that emotional distress does not, by itself, cause inflammatory bowel disease (IBD), it is often a reaction to chronic diseases and can lower your tolerance to pain. This newsletter will address several support strategies that may help you cope with IBD: attending support groups, seeking individual psychotherapy, or accessing online support alternatives. Whether you are a new patient or have had IBD for years, these options can help you develop strategies to cope with embarrassing or painful symptoms and manage fears about possible surgeries and unexpected complications that may accompany your illness.

Back to Top

Support Groups

What is a support group?

A support group is simply a group of people who meet on a regular basis, share common issues, and support one another through their experiences. Many people with IBD find it therapeutic to meet with other people who have the illness. Members typically share a similar diagnosis (or have family members with similar diagnoses), and the group provides a venue for discussion.

Support groups are as varied as the needs of those who join them. They may be led by a layperson, peer, or a professional, and their focus may be purely supportive or may also include an educational component. Membership may include only the person with the illness or extend to the family. A group may be open to new members on an ongoing basis or closed for a certain period of time.

Why do people participate in support groups? How do they benefit?

Support groups have been used for decades to help individuals and family members cope with chronic illness or mental health issues. Although some people do not feel a need for support beyond their family and friends, others find it helpful to connect with people who are facing similar health–related challenges. Studies have shown that patients who attend support groups have better health outcomes than do patients who do not.1 Many people find comfort in knowing that they are not alone and benefit from talking about their experiences in a safe environment. Support groups provide a place to share coping tips for symptoms and common feelings that accompany chronic illness, like isolation, loneliness, guilt, fear, stigmatization, depression, and hopelessness. These groups may help you to find the motivation you need to take a more active role in your treatment, stick to your treatment plan, or tap into community resources. Support groups can also be a great place to learn about recent scientific advances and new treatment options. If you have recently been diagnosed with IBD, it is likely that you will initially do more "taking" than "giving" when you first join a support group. But, after some time, it is likely that you will quickly find that you are also able to help others help themselves, and that can be very rewarding.

What happens at a typical support group meeting?

Support group meetings usually begin with an icebreaker activity or an opportunity for members to introduce themselves. Each meeting may then focus on a question or topic, like lifestyle issues, dealing with your doctor, feelings about your treatment, coping strategies, nutrition and diet, surgical options, or understanding diagnostic tests. On other occasions, the focus of the meeting may be determined by a guest speaker, such as a physician, a dietitian, or a mental health professional.

You can use the following list of questions to help you decide whether a particular support group might be a good fit for you.

 

After attending a support group, think about to how it made you feel. You will know that you have found a support group that's a good match for you if you receive encouragement and support from other group members, you learn helpful information, and your symptoms seem easier to manage. Although most support groups have each member's best interest at heart, some may not. Be wary of a support group that centers around complaining and negativity, allows a few people to dominate the discussions, or pressures you to purchase a product or service. It is important for you to remember that support groups are not a substitute for individualized medical management by your physician, and you should discuss any medical information you receive with your physician.

How to find a support group?

The Crohn's and Colitis Foundation of America (CCFA) has over 40 staffed and volunteer regional chapters and affiliates nationwide. Each year these chapters hold more than 300 free support groups where people with IBD and their family members can connect to others who are struggling to cope with IBD. CCFA support groups usually meet monthly or every other month and all CCFA support group facilitators (many of whom may also be psychologists, social workers, or nurses) are trained volunteers. To find a CCFA support group near you, check their website (http://www.ccfa.org) which has links to chapters by state.

The United Ostomy Associations of America (UOAA) also organizes self–help groups where people meet to discuss facts about ostomies and share information about the experience of living with an ostomy. To find a group near you, check the UOAA's website (http://www.uoaa.org/supportgroups.shtml), which lists affiliated groups.

If the above options are not available in your community, your doctor or someone else with IBD may be able to recommend a support group near you.

Back to Top

Individual Psychotherapy

What is psychotherapy?

Psychotherapy, which is also sometimes referred to as "talk therapy" or "counseling," involves talking with a trained mental health professional to help you gain insight into your feelings, change behaviors, resolve problems, or learn how to deal with emotions like stress, grief, loss, fear, and sadness. It is based on the theory that people can improve their emotional well–being and mental health by talking about their problems with a therapist who, in turn, helps them find better ways to cope, solve problems, and set realistic goals for improvement.

Who benefits from psychotherapy?

Psychotherapy can give you an opportunity to explore some personal issues in an individual setting. If you are not comfortable with the idea of a support group, but need help coping with your diagnosis or feel you are becoming depressed because of your IBD, psychotherapy may help. In a recent study of 302 patients with IBD, 20% expressed a need for psychotherapy due to impaired social functioning, anxiety, and worries about the impact of IBD.2 In another study, patients with Crohn's disease participating in 20 hours of basic short–term psychodynamic psychotherapy experienced reduced hospital days and sick leave days during the follow–up period, when compared to a control group.3

Are there different types of psychotherapists?

Professionals who provide psychotherapy include psychiatrists, clinical psychologists, and licensed clinical social workers. A psychiatrist is a doctor who has completed medical school, at least one year of internship, and three years of specialized psychiatric residency training. Psychiatrists specialize in the diagnosis, treatment, and prevention of mental illness. Some psychiatrists provide psychotherapy and others work with a psychologist or social worker who conducts the therapy while the psychiatrist supervises treatment and provides medical oversight. All psychiatrists are licensed to prescribe medication.

Clinical psychologists apply psychological principles to the treatment of mental, emotional, and behavioral disorders through a broad range of psychotherapies. Most have a master's or doctoral degree in psychology and also complete a clinical residency, however each state has different requirements regarding the educational background necessary for licensure.

Licensed clinical social workers are also trained in psychotherapy. They usually have a master's degree in social work, and their coursework tends to be more hands on and less theoretical than doctorally trained therapists. A licensed clinical social worker can help you deal more effectively with the psychological and physical stress of living with a chronic illness.

How to find a therapist?

The best way to find a therapist is through referrals. Try asking your physician, others with IBD, or friends and colleagues. You may also want to check with your health insurance company about referrals or to see if there are any limitations regarding your choices. Health insurance typically covers the cost for a set number of sessions. If you do not have health insurance, many therapists offer a sliding fee scale based on your income. You can use the following list of questions to help you choose a psychotherapist who makes you feel safe, comfortable, and at ease.

 

In addition to possessing the standard skills, it is important that the therapist be genuinely interested in treating patients with IBD. Ideally the therapist will be familiar with the normal and erratic course of the disease, as well as with the various drug therapies used and the potential complications that may arise.

What to expect?

Psychotherapy sessions are usually 45 to 60 minutes long and take place in a small office located in a medical clinic, an office building, or sometimes a private home. The therapist will typically use the first session or two to learn about your situation and issues, and you may be asked to fill out forms about your physical and emotional health.

During subsequent sessions, your therapist will encourage you to talk about your thoughts, how you are feeling, and what is troubling you. The actual treatment will vary depending on the philosophical affiliation of the therapist. You may find that it's difficult to open about your feelings, or you may find yourself crying or angry during a session. A good therapist will help you gain the confidence to express yourself and help you cope with any strong feelings that emerge. Over time, you should find that you feel better about yourself and are better able to cope with IBD.

Back to Top

Online Support – Message Boards and Chat Rooms

What are message boards and chat rooms?

The Internet provides a number of ways to communicate online (i.e., "virtually") with people whose situations are similar to yours. Message boards, which are also called "discussion boards" or "forums," are like virtual bulletin boards. Participants post messages (called "posts") about specific topics, such as ulcerative colitis, Crohn's disease, ostomies, parenting children with IBD, etc. Usually, anyone can choose to read some or all of the messages, but you typically must register to reply to messages or post a new message. The beauty of a message board is that participants don't have to be online simultaneously. You can post a message one evening and others post responses over the next few days.

Chat rooms operate like message boards, but in real time. There is no delay in the exchange in information, meaning that participants must be online simultaneously. Chat rooms resemble telephone conversations – when participants log off, the conversation is over. With either message boards or chat rooms, a moderator may monitor the content to prevent inappropriate posts.

What are the advantages and disadvantages of message boards and chat rooms?

One advantage is that if you are not feeling well enough to leave your house to attend a support group, you can participate on a message board or in a chat room from the comfort of your home. Another advantage is that online support is global and available around the clock, whereas you can attend a support group only if it's scheduled at a place and time that is convenient for you. Finally, if you are uncomfortable sharing information with people you don't know, message boards and chat rooms allow you to maintain your anonymity.

Although the anonymity found online may be appealing, it can also be a disadvantage, since it is difficult to know if any other participants are being truthful about their identity and what conditions they have. As you feel increasingly comfortable with an online group, you may be inclined to reveal more information about yourself, but always be careful about sharing your full name, your address, or your phone number with online strangers. Finally, remember that health–related information you receive online may not be accurate. If you hear something disturbing or that doesn't seem right, discuss it with your doctor.

How to find online support?

The CCFA sponsors message boards called "online forums," which are moderated by CCFA staff. Topic areas include newly diagnosed, emotional wellness, dealing with surgery, parents and caregivers, women's issues, and men's issues. Anyone can go to www.ccfacommunity.org/Forums.aspx to read what is posted, but you need to register to post comments or questions.

You can find links to other support groups through the following web sites:

 

Back to Top

Conclusion

Support groups, psychotherapy, and/or online support can complement the care you receive from your physician. Although none are a substitute for medical care, they may teach you new coping skills and encourage you to stay on course with your treatment. Opening up to others can be difficult at first, but you are likely to find that doing so will give you a greater sense of self–esteem and empowerment as you learn to cope and adapt to life with IBD.




  1. http://www.mefmaction.net/SupportGroups/BenefitofSupportGroups/tabid/263/Default.aspx
  2. Miehsler W. Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis. 2008;14:1273-1280.
  3. Deter HC et al. Psychological treatment may reduce the need for health care in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;12:745-752.


Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter